Orthoclone OKT3

Active Ingredient(s): Muromonab-CD3
FDA Approved: * September 14, 1992
Pharm Company: * ORTHO BIOTECH
Category: Immunosuppressive

Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants.[1][2] It is a monoclonal antibody targeted at the CD3 receptor,[3] a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.[2] Contents 1 History 2 Indications 3 Pharmacodynamics and chemistry 4 ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.